MDWD
MediWound Ltd.
MDWD has slightly lower modeled downside risk, despite its lower overall score.
NVO
Novo Nordisk A/S
NVO has the edge over MDWD overall, supported by stronger fundamentals.
MDWD Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
MDWD's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
MDWD PE Valuation
MDWD has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
MDWD Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect MDWD's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
MDWD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.60 | +$1.04 |
| Q1 2026 | -$2.26 | -$0.17 |
| Q4 2025 | -$2.10 | +$0.97 |
| Q3 2025 | -$1.90 | +$1.00 |
| Q2 2025 | -$2.64 | -$0.48 |
| Q1 2025 | -$2.09 | -$0.71 |
| Q4 2024 | -$3.07 | -$2.30 |
| Q3 2024 | -$2.90 | -$1.14 |
MDWD is still losing money, but far less than before: $1.60 per share over the past year, against $3.85 at its worst in late 2022.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over MDWD on earnings quality, reporting a profit while its opponent remains loss making.
MDWD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $3.1M | -46% |
| Q1 2026 | $1.5M | -63% |
| Q4 2025 | $1.9M | -68% |
| Q3 2025 | $5.4M | +25% |
| Q2 2025 | $5.7M | +13% |
| Q1 2025 | $4M | -20% |
| Q4 2024 | $5.8M | +9.4% |
| Q3 2024 | $4.4M | -8.8% |
MDWD's revenue has slid since its 2022 peak: $3M last quarter, down 46% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -306% | -206 points |
| Q1 2026 | -541% | -409 points |
| Q4 2025 | -418% | -314 points |
| Q3 2025 | -120% | -3.5 points |
| Q2 2025 | -100% | -12 points |
| Q1 2025 | -132% | -57 points |
| Q4 2024 | -104% | -31 points |
| Q3 2024 | -117% | -53 points |
MDWD's operating margin was −306% last quarter, down 206 points from the same quarter a year ago, near the bottom of its range since 2019.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO has the edge over MDWD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over MDWD on profitability, with a higher operating margin.
MDWD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$10.1M | -$3.3M |
| Q1 2026 | -$8.6M | -$3.5M |
| Q4 2025 | -$5.5M | -$3M |
| Q3 2025 | -$4.3M | +$664K |
| Q2 2025 | -$6.8M | -$166K |
| Q1 2025 | -$5.1M | +$193K |
| Q4 2024 | -$2.4M | +$2.4M |
| Q3 2024 | -$4.9M | -$12K |
MDWD has burned cash in almost every quarter: −$28M over the past year, against −$19M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over MDWD on cash generation, producing positive trailing cash flow while its opponent burns cash.
MDWD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +9.8K shares |
| 1 year | +19% | +2M shares |
| 3 years | +40% | +3.7M shares |
| 5 years | +231% | +9M shares |
| Available history | +232% | +9M shares |
MDWD has 13M diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | $747,000 |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
MDWD spent $747,000 buying back its own shares over the past year, after none the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over MDWD on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
MDWD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -11.2x | Net Cash |
| Q4 2023 | -2.1x | Net Cash |
| Q1 2020 | -1.1x | Net Cash |
| Q4 2019 | -1.3x | Net Cash |
| Q3 2019 | -0.5x | Net Cash |
MDWD has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
MDWD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 59.4 | Neutral |
MDWD's weekly RSI is 44 (neutral) and its Stochastic is 59 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
MDWD PE vs Healthcare Sector
| Metric | MDWD | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
MDWD has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
MDWD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.0 | 0.5% below |
| 20 week MA | $13.5 | 4.1% below |
| 50 week MA | $15.5 | 17% below |
| 100 week MA | $16.9 | 23% below |
| 200 week MA | $15.1 | 14% below |
MDWD is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over MDWD on trend strength, trading above more of its moving averages.
MDWD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.1 | $28.6 | +35% |
| 2021 | $28.6 | $15.8 | -45% |
| 2022 | $15.8 | $11.5 | -27% |
| 2023 | $11.5 | $10.2 | -12% |
| 2024 | $10.2 | $17.7 | +74% |
| 2025 | $17.7 | $18.8 | +6.2% |
| 2026 YTD | $18.8 | $13.0 | -31% |
MDWD has finished lower in three of the last six years. It's down 31% so far in 2026.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over MDWD on returns for 2026, with the stronger performance.